Barclays lowered the firm’s price target on Vor Bio to $10 from $15 and keeps an Overweight rating on the shares. The firm said in a research note on Friday that the price target decrease reflects recent dilution and longer timelines to market given the pace of enrollment in the VOR33 study.
Published first on TheFly
